Compare HCM & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCM | VERA |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2015 | 2021 |
| Metric | HCM | VERA |
|---|---|---|
| Price | $13.45 | $26.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $21.14 | ★ $71.36 |
| AVG Volume (30 Days) | 37.1K | ★ 1.3M |
| Earning Date | 07-30-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.11 | N/A |
| Revenue Next Year | $11.97 | $725.78 |
| P/E Ratio | $5.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $25.56 |
| 52 Week High | $16.33 | $56.05 |
| Indicator | HCM | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 38.28 |
| Support Level | $13.00 | N/A |
| Resistance Level | $14.74 | $36.95 |
| Average True Range (ATR) | 0.38 | 1.62 |
| MACD | -0.10 | -0.43 |
| Stochastic Oscillator | 17.90 | 18.51 |
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.